ORR in this cohort was 47% with a median progression-free survival of 5.5 months.228 The antibody-drug conjugate trastuzumab-deruxtecan showed an ORR of 36.4% in 22 HER2-positive patients with CCA, including two complete responses, in the HERB phase II trial.229 Trastuzumab-deruxtecan was further assessed in 267 patients with metastatic CCA in the phase II DESTINY-PanTumor02 trial.230 Forty-one patients with CCA were included and showed an ORR of 22.0%. Here, ERBB2 is linked to cholangiocarcinoma.